ADC Therapeutics (ADCT) Enterprise Value (2019 - 2026)
ADC Therapeutics (ADCT) posted Enterprise Value of -$231.0 million for Q1 2026, up 11.61% sequentially from -$261.3 million in Q4 2025, and down 18.65% YoY from -$284.0 million in Q1 2025.
ADC Therapeutics (ADCT) Enterprise Value (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Enterprise Value for 8 years, with the latest figure at -$231.0 million in Q1 2026.
- Quarterly Enterprise Value fell 18.65% year-over-year to -$231.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.0 million (down 18.65% YoY) and the FY2025 annual result came in at -$261.3 million, down 4.17% from the prior year.
- Enterprise Value improved to -$231.0 million in Q1 2026 per ADCT's latest filing, from -$261.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$194.7 million in Q1 2025 and troughed at -$430.9 million in Q1 2022.
- A 5-year average of -$294.6 million and a median of -$278.6 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2026: Enterprise Value soared 30.03% in 2022, then dropped 18.65% in 2026.
- Over 5 years, Enterprise Value stood at -$326.4 million in 2022, then climbed by 14.66% to -$278.6 million in 2023, then rose by 9.95% to -$250.9 million in 2024, then dropped by 4.17% to -$261.3 million in 2025, then grew by 11.61% to -$231.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$231.0 million, -$261.3 million, and -$234.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | -219.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -219.11 Mn |
| Mar 31, 2026 | -231.01 Mn |
| Dec 31, 2025 | -261.34 Mn |
| Sep 30, 2025 | -234.74 Mn |
| Jun 30, 2025 | -264.56 Mn |
| Mar 31, 2025 | -194.70 Mn |
| Dec 31, 2024 | -250.87 Mn |
| Sep 30, 2024 | -274.30 Mn |
| Jun 30, 2024 | -300.12 Mn |
| Mar 31, 2024 | -234.30 Mn |
| Dec 31, 2023 | -278.60 Mn |
| Sep 30, 2023 | -310.41 Mn |
| Jun 30, 2023 | -347.51 Mn |
| Mar 31, 2023 | -310.55 Mn |
| Dec 31, 2022 | -326.44 Mn |
| Sep 30, 2022 | -380.86 Mn |
| Jun 30, 2022 | -376.78 Mn |
| Mar 31, 2022 | -430.87 Mn |
| Dec 31, 2021 | -466.54 Mn |
| Sep 30, 2021 | -530.19 Mn |